SGIOY Shionogi & Co., Ltd.
Shionogi & Co., Ltd. (SGIOY) is expected to report earnings on January 28, 2027, before the market open. The consensus earnings estimate is $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.6% since its last earnings release on October 29, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Charts powered in part by Lightweight Charts™ by TradingView.